Jump to main content
Takeda will discontinue global manufacturing of NATPARA by the end of 2024. Learn How This May Affect You
NATPARA logo.
NATPARA logo.

Managing
Hypoparathyroidism

Managing hypoparathyroidism requires careful monitoring2

In stable patients:

  • Serum calcium, phosphorous/phosphate, magnesium, BUN/creatinine and eGFR at least yearly
  • 24-hour urine collection for calcium and creatinine yearly

During dose adjustments:

  • More frequent monitoring, often several times per week, until a stable serum calcium concentration is achieved

For dosing and monitoring specific to NATPARA, click here.

Aim for low-normal, albumin-corrected total serum calcium levels2,3

For patients being treated for hypoparathyroidism, serum calcium levels are typically maintained at the lower end of the normal range (approximately 8.0 to 9.0 mg/dL).2

Albumin-corrected total serum
calcium levels1-4

Graph showing the target calcium range for people being targeted for hypoparathyroidism.

References: 1. NATPARA [package insert]. Shire Pharmaceuticals, Inc. 2. Brandi ML, Bilezikian JP, Shock D, et al. J Clin Endocrinol Metab. 2016;101(6):2273-2283. doi: 10.1210/jc.2015-3907. 3. Shoback D. N Engl J Med. 2008;359(4):391-403. 4. Fong J, Khan A. Can Fam Physician. 2012;58(2):158-162.

NATPARA® and the NATPARA Logo® are registered trademarks of Takeda Pharmaceuticals, U.S.A,. Inc.